Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,815 across all filing types
Latest filing 2026-03-02 Director's Dealing
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Director's Dealing Classification · 1% confidence The document is a formal notification of transactions in company shares by managerial employees (directors and executives), specifically detailing the vesting of restricted stock units. This aligns perfectly with the definition of 'Director's Dealing' (DIRS), which covers reports of personal share transactions by company directors and executives.
2026-03-02 English
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Director's Dealing Classification · 1% confidence The document is titled 'Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons'. It explicitly references Article 19 of Regulation No. 596/2014 (Market Abuse Regulation), which governs the disclosure of transactions by persons discharging managerial responsibilities (PDMRs). This is a standard regulatory disclosure for insider trading/director dealings. While the document mentions an attachment, the text itself provides the context and purpose of the disclosure, fitting the 'Director's Dealing' category.
2026-03-02 English
Transactions in Connection with Share Buy-back Program
Transaction in Own Shares Classification · 1% confidence The document is a formal company announcement from Genmab detailing specific transactions executed under a share buy-back program. It provides a table of daily share repurchases, the average price, and the total value, as well as the updated treasury share position. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS), which covers reports of a company buying back its own shares.
2026-03-02 English
Transactions in Connection with Share Buy-back Program
Transaction in Own Shares Classification · 1% confidence The document is a company announcement detailing specific transactions executed under a share buy-back program, including dates, number of shares, average prices, and total values. This aligns perfectly with the definition of 'Transaction in Own Shares' (POS), which covers reports of a company buying back its own shares.
2026-03-02 English
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Director's Dealing Classification · 1% confidence The document is a formal disclosure of transactions in company shares by managerial employees (Jan G. J. van de Winkel, Anthony Pagano, and Martin Schultz). It explicitly references Article 19 of Regulation No. 596/2014 on Market Abuse, which is the standard regulatory framework for reporting insider/director dealings. The content details the grant of Restricted Stock Units to these individuals, which falls directly under the definition of 'Director's Dealing'.
2026-02-27 English
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Director's Dealing Classification · 1% confidence The document is titled 'Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons'. It explicitly references Article 19 of Regulation No. 596/2014 (Market Abuse Regulation), which governs the disclosure of insider/director dealings. While the document mentions an attachment, the core purpose of the text is to report these specific transactions as required by regulatory standards. Therefore, it is classified as a Director's Dealing (DIRS) report.
2026-02-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.